CA3169550A1 - Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras - Google Patents

Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras Download PDF

Info

Publication number
CA3169550A1
CA3169550A1 CA3169550A CA3169550A CA3169550A1 CA 3169550 A1 CA3169550 A1 CA 3169550A1 CA 3169550 A CA3169550 A CA 3169550A CA 3169550 A CA3169550 A CA 3169550A CA 3169550 A1 CA3169550 A1 CA 3169550A1
Authority
CA
Canada
Prior art keywords
seq
strand
antisense
sense strand
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3169550A
Other languages
English (en)
Inventor
Chad PECOT
Salma H. Azam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/842,404 external-priority patent/US11180759B2/en
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CA3169550A1 publication Critical patent/CA3169550A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'inhibition de l'expression de séquences mutantes de KRAS au moyen de l'interférence par l'ARN.
CA3169550A 2020-04-07 2021-04-07 Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras Pending CA3169550A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/842,404 2020-04-07
US16/842,404 US11180759B2 (en) 2016-01-19 2020-04-07 Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
PCT/US2021/026147 WO2021207339A1 (fr) 2020-04-07 2021-04-07 Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras

Publications (1)

Publication Number Publication Date
CA3169550A1 true CA3169550A1 (fr) 2021-10-14

Family

ID=78024140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3169550A Pending CA3169550A1 (fr) 2020-04-07 2021-04-07 Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras

Country Status (4)

Country Link
EP (1) EP4100530A4 (fr)
JP (1) JP2023521383A (fr)
CA (1) CA3169550A1 (fr)
WO (1) WO2021207339A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190995A2 (fr) * 2007-09-18 2010-06-02 Intradigm Corporation Compositions comprenant un arnsi de k-ras et procédés d utilisation
EP2414374A4 (fr) * 2009-04-03 2013-09-25 Dicerna Pharmaceuticals Inc Procédés et compositions pour l'inhibition spécifique de kras par de l'arn double brin asymétrique
KR20150004414A (ko) * 2012-05-02 2015-01-12 노파르티스 아게 Kras-관련 질환을 치료하기 위한 유기 조성물
AU2015249265A1 (en) * 2014-04-25 2016-11-03 Baylor College Of Medicine Multiple targeted RNAi for the treatment of cancers
WO2016201323A1 (fr) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Utilisation d'exosomes pour le traitement de maladies
EP3405576A4 (fr) * 2016-01-19 2019-09-18 The University of North Carolina at Chapel Hill Procédés et compositions utilisant l'interférence par arn pour l'inhibition de kras
MA45470A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
US20210115449A1 (en) * 2018-04-19 2021-04-22 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes

Also Published As

Publication number Publication date
WO2021207339A1 (fr) 2021-10-14
EP4100530A1 (fr) 2022-12-14
EP4100530A4 (fr) 2024-05-22
JP2023521383A (ja) 2023-05-24

Similar Documents

Publication Publication Date Title
US20220073923A1 (en) Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras
JP6621409B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
US10619159B2 (en) Methods and compositions using RNA interference for inhibition of KRAS
CN107921147B (zh) 一种新的前体miRNA及其在肿瘤治疗中的应用
US8895509B2 (en) MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
US8618073B2 (en) Use of miR-29 for cell protection
US20200188424A1 (en) Compositions and methods for the treatment of fibrotic diseases
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
EP3679140B1 (fr) Compositions stabilisées de petits arn activateurs (parna) de cebpa et procédés d'utilisation
JP6608284B2 (ja) 癌の治療に使用されるｒｎａトランススプライシング分子（ｒｔｍ）
CN116113697A (zh) 用于治疗癫痫的方法和组合物
CA3169550A1 (fr) Procedes et compositions utilisant l'interference par l'arn et des oligonucleotides antisens pour l'inhibition de kras
WO2023250366A1 (fr) Procédés et compositions pour l'inhibition d'irf4
WO2011065677A2 (fr) Composition pharmaceutique pour le traitement du cancer
CA3221985A1 (fr) Molecules d'arnsi chimeriques inversees et leurs procedes d'utilisation
JP2023522622A (ja) Ｔｄｐ－４３及びｆｕｓ凝集を抑制するための組成物及び方法
US20130259926A1 (en) BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF
CN114306367B (zh) 一种含有C/EBPα-saRNA的组合物
WO2021231518A1 (fr) Conjugués de ligand lié à un acide nucléique et leur utilisation pour l'administration à des cellules
WO2015155718A1 (fr) Manipulation de cib1 destinée à tuer des cellules cancéreuses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825

EEER Examination request

Effective date: 20220825